Verve Therapeutics Q4 GAAP EPS $(0.69) Beats $(0.82) Estimate, Sales $5.14M Beat $1.17M Estimate; Cash, Cash Equivalents and Marketable Securities of $624M With Cash Runway into Late 2026

Author: Benzinga Newsdesk | February 27, 2024 08:45am
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.82) by 15.85 percent. This is a 2.99 percent decrease over losses of $(0.67) per share from the same period last year. The company reported quarterly sales of $5.14 million which beat the analyst consensus estimate of $1.17 million by 339.57 percent. This is a 408.20 percent increase over sales of $1.01 million the same period last year.

Posted In: VERV